We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.85 | 2.80 | 2.90 | 2.85 | 2.85 | 2.85 | 360,349 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.17 | 135.84M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/6/2014 19:09 | Cube Thanks jl | jimmyloser | |
24/6/2014 10:27 | That would be useful, there's been a lot of loyalty shown to this stock for several years now and I think people need to start seeing not just the right words but some right actions too. | aruntim | |
24/6/2014 10:00 | Going to phone IP later, see if I can get anything out of him! don't expect any Price sensitive info, but just a little reassurance all is on track! Will let you know Jimmy and all. Need some kind of update..:0)) | cube boss | |
23/6/2014 09:55 | Our biggest market - currently! | jimmyloser | |
18/6/2014 13:42 | European Patent Granted For MPL-Based Sublingual Vaccines Allergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that the European Patent office has granted a broad technology patent relating to the Company's family of MPL®-based sublingual allergy vaccines. This patent (jointly held with Corixa Inc) covers the use of glycolipid adjuvant administered sublingually with one or more antigens for use in the treatment of allergy or other diseases (infections, cancer or autoimmunity). Allergy Therapeutics' new generation of allergy vaccines use MPL®, an innovative TLR4-agonist, as an adjuvant to boost and accelerate the immune response of an allergy vaccine. Allergy Therapeutics has already conducted and previously reported results of a double-blind, placebo controlled, dose ranging Phase IIa MPL-based oral allergy vaccine study. The study (Study 103) was conducted in 80 grass-sensitive human subjects and involved the addition of MPL to Allergy Therapeutics' ORALVAC® grass pollen vaccine. This was the first time that any adjuvant had ever been clinically tested in an oral allergy vaccine and was also the first ever examination of oral delivery of MPL in humans. The results demonstrated that the vaccine was well tolerated and that, following an eight week treatment period, clinical symptoms improved and were accompanied by a characteristic pattern of immune response. Datamonitor estimates that the prevalence of allergic rhinitis ("AR") varies from 9.2% (Germany) to 17.2% (FRANCE) and that in the five major European markets the diagnosed AR population over 20 years of age is 28.3 million. However, under-diagnosis is substantial, with an estimated 44% of the AR population not diagnosed1. The value of the immunotherapy market in Europe is estimated to be more than 550 million. The development of a convenient, effective, short course, well tolerated oral allergy vaccine would have significant implications for allergy therapy and redefine the market for allergy products. Currently available oral allergy vaccines require prolonged treatment periods associated with poor patient compliance and low efficacy. | jimmyloser | |
18/6/2014 09:36 | A Market that they should be addressing | moneyman18 | |
17/6/2014 19:08 | ??????????????? from where we came is where we'll rest ?????????????? | jimmyloser | |
15/6/2014 12:13 | Hopefully though not "glowing in the dark". | algernon2 | |
13/6/2014 10:33 | Need to walk the Dog Cube its a duster.(TRP). Guess we'll see you back on here more now? | algernon2 | |
04/6/2014 16:46 | Good news in Germany on birch testing Relax - this is slow burn but behaving well. impo/dyor | jimmyloser | |
04/6/2014 15:01 | Can we please just shot up to 45p within the next six weeks, I'd rather relax a little more on my holiday! | aruntim | |
04/6/2014 14:33 | Do we have any diary dates/events scheduled for AGY? FG | farmer george | |
04/6/2014 14:05 | Hay fever really bad this year, Lets HOPE AGY are cashing in with their products | moneyman18 | |
02/6/2014 12:23 | Must have had sleep in my eyes...Lol :0) | cube boss | |
02/6/2014 08:29 | Touch of BLUE this am, am I seeing correctly? May it continue...:0)) | cube boss | |
23/5/2014 17:30 | Cube You and t'dog can come back home now - it worked! lol | jimmyloser | |
23/5/2014 09:28 | Just setting off now Jimmy! the dog has a great RAIN coat...:0)) Needs news here guys. Have a great weekend..:0)) | cube boss | |
22/5/2014 21:33 | May need to upgrade it a whippet if you do! | aruntim | |
22/5/2014 18:29 | Cube Any plans to walk the dog tomorrow....Lands End to John O' Groats for instance? | jimmyloser | |
20/5/2014 14:46 | This is swinging on nothing more than intra-day sentiment lol impo. | jimmyloser | |
20/5/2014 13:15 | are we going to get to buy at 17p | bad robot | |
19/5/2014 16:10 | Stick hold tight - impo/DYOR jimmyloser 16 May'14 - 15:19 - 2622 of 2659 0 0 edit jimmyloser 15 May'14 - 07:30 - 2610 of 2621 0 0 edit Take a closer look and read between the lines. We have a serious buyer | jimmyloser |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions